Phase 3
Completed N=223
Meloxicam for Pain Management After Total Joint Arthroplasty (TJA)
Total Knee Replacement · Total Hip Replacement
Source: ClinicalTrials.gov NCT05291598 ↗
Enrolled (actual)
223
Serious AEs
0.0%
Results posted
Aug 2024
Primary outcomePrimary: Pain Measured by the Numeric Rating Scale — 3.34; 3.32 units on a scale
◆ Published Evidence
Not yet cited
0citations
Intravenous Meloxicam Versus Ketorolac for Pain Control Following Total Joint Arthroplasty: A Double-Blind Randomized Controlled Trial.
Summary
The purpose of this project is to determine if a change in patient reported pain, nausea and vomiting after total knee and hip arthroplasty could be observed with the substitution of Intravenous meloxicam for ketorolac in the current established peri-operative pain protocol and if these changes lead to a decrease in opioid consumption (in morphine equivalents).
Linked Publications
-
Intravenous Meloxicam Versus Ketorolac for Pain Control Following Total Joint Arthroplasty: A Double-Blind Randomized Controlled Trial.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Pain Measured by the Numeric Rating Scale |
4.06; 3.75 | — |
| SECONDARY Nausea Score as Measured by a Likert Scale |
0.48; 0.29 | — |
| SECONDARY Length of Stay as Measured by Hours in the Hospital |
37.87; 41.56 | — |
| SECONDARY Length of Stay as Measured by Hospital Nights |
1.51; 1.63 | — |
| SECONDARY Length of Stay as Measured by Same Day Discharges |
23; 10 | — |
| SECONDARY Opioid Consumption as Measured by Morphine Milligram Equivalents (MME) |
20.59; 28.21 | — |
| SECONDARY Renal Injury as Measured by the Change in Creatinine Levels |
0.09; 0.09 | — |
Eligibility Criteria
Inclusion Criteria
- Patients over the age of 18,
- Patients undergoing primary total knee or primary total hip replacement at the University of Miami Hospital,
- Patients that have capacity to provide medical consent
Exclusion Criteria
- All patients under the age of 18
- Prisoners, diabetics, increased risk of bleeding, and pregnant women.
- Patients with prior surgery or history of infection on the joint of interest.
- Patients with an estimated glomerular filtration rate (eGFR) <50 ml/min
- Patients on dialysis or renal transplant.
- Patients on steroid preoperatively.
- Allergy to sulfas
- Inability to provide medical consent.
- Any condition that, in the opinion of the investigator, would compromise the well-being of the patient or the study or prevent the patient from meeting or performing study requirements will exclude the participant.
Data sourced from ClinicalTrials.gov (NCT05291598) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.